Skip to main content Accessibility help

Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders

  • Kevin Whelan (a1)


The gastrointestinal microbiota is a complex ecosystem with each human individual hosting at least 160 different bacterial strains. Our understanding of its role is rapidly expanding as a result of the molecular microbiological techniques that can accurately characterise its composition and ‘omics’ technologies that measure its metabolic activity. Since 1995, extensive research has investigated the prebiotic concept, which describes how supplementation of some non-digestible oligosaccharides can stimulate the growth and/or activity of specific genera including bifidobacteria. However, the vast majority of studies are in healthy human subjects, with few undertaken in patients with disorders relevant to clinical nutrition. Marked alterations of the luminal microbiota have been demonstrated in patients with digestive disorders, highlighting mechanisms through which they might be involved in their pathogenesis, including higher clostridia in patients who develop diarrhoea during enteral nutrition and the influence of bifidobacteria on intestinal dendritic cell phenotype in Crohn's disease. The impact of prebiotics on the intestinal microbiota of healthy people has not been consistently replicated in patients with digestive disorders. For example, a number of studies show that inulin/oligofructose do not increase bifidobacteria in enteral nutrition and Crohn's disease. Indeed, in Crohn's disease and irritable bowel syndrome there is evidence that some prebiotics in high doses worsen functional symptoms. Unlike healthy human subjects, patients experience a number of issues that may alter their gastrointestinal microbiota (disease, antibiotics and inflammation) and the use of microbiota modifying therapies, such as prebiotics, do not always elicit the same effects in patients as they do in healthy people.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders
      Available formats


Corresponding author

Corresponding author: Professor K. Whelan, fax + 44 20 78 48 41 85, email


Hide All
1. Sekirov, I, Russell, SL, Antunes, LC et al. (2010) Gut microbiota in health and disease. Physiol Rev 90, 859904.
2. Eckburg, PB, Bik, EM, Bernstein, CN et al. (2005) Diversity of the human intestinal microbial flora. Science 308, 16351638.
3. Qin, J, Li, R, Raes, J et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 5965.
4. Arumugam, M, Raes, J, Pelletier, E et al. (2011) Enterotypes of the human gut microbiome. Nature 473, 174180.
5. Claesson, MJ, Cusack, S, O'Sullivan, O et al. (2011) Composition, variability and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 108, Suppl. 1, S4586S4591.
6. Tissier, H (1898) Recherchessur la floreintestinale de nourissons (Research on the intestinal flora of infants). PhD Thesis, University of Paris, France.
7. Wu, GD, Chen, J, Hoffmann, C et al. (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105108.
8. Faith, JJ, McNulty, NP, Rey, FE et al. (2011) Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 333, 101104.
9. Gibson, GR & Roberfroid, MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125, 14011412.
10. Roberfroid, M, Gibson, GR, Hoyles, L et al. (2010) Prebiotic effects: metabolic and health benefits. Br J Nutr 104, Suppl. 2, S1S63.
11. Sonnenburg, ED, Zheng, H, Joglekar, P et al. (2010) Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell 141, 12411252.
12. Van Loo, J, Coussement, P, de Leenheer, L et al. (1995) On the presence of inulin and oligofructose as natural ingredients in the western diet. Crit Rev Food Sci Nutr 35, 525552.
13. Dunn, S, Datta, A, Kallis, S et al. (2011) Validation of a food frequency questionnaire to measure intakes of inulin and oligofructose. Eur J Clin Nutr 65, 402408.
14. Moshfegh, AJ, Friday, JE, Goldman, JP et al. (1999) Presence of inulin and oligofructose in the diets of Americans. J Nutr 129, Suppl. 7, S1407S1411.
15. Whelan, K, Abrahmsohn, O, David, GJ et al. (2011) Fructan content of commonly consumed wheat, rye and gluten-free breads. Int J Food Sci Nutr 62, 498503.
16. Henderson, L, Gregory, J & Swan, G. (2002) National Diet and Nutrition Survey: Adults Aged 19–64, vol. 1. Norwich: HMSO.
17. Biesiekierski, JR, Rosella, O, Rose, R et al. (2011) Quantification of fructans, galacto-oligosaccharides and other short-chain carbohydrates in processed grains and cereals. J Hum Nutr Diet 24, 154176.
18. Gibson, GR, Beatty, ER, Wang, X et al. (1995) Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108, 975982.
19. Bouhnik, Y, Vahedi, K, Achour, L et al. (1999) Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr 129, 113116.
20. Davis, LM, Martínez, I, Walter, J et al. (2010) A dose dependent impact of prebiotic galacto-oligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol 144, 285292.
21. Whelan, K, Bartlett, A, Datta, A et al. (2009) Dietary and non-dietary factors associated with the concentration of major GI microbiota in healthy subjects. Proc Nutr Soc 68, OCE1(E22).
22. Whelan, K (2012) Modification of the gastrointestinal microbiota and its application to clinical nutrition. J Hum Nutr Diet 25, 297299.
23. Lebak, KJ, Bliss, DZ & Savik, K (2003) What's new on defining diarrhea in tube-feeding studies? Clin Nurs Res 12, 174204.
24. Whelan, K, Judd, PA & Taylor, MA (2003) Defining and reporting diarrhoea during enteral tube feeding: do health professionals agree? J Hum Nutr Diet 16, 2126.
25. Majid, HA, Emery, PW & Whelan, K (2012) Definitions, attitudes and management practices in relation to diarrhea during enteral nutrition: a survey of patients, nurses and dietitians. Nutr Clin Pract 27, 252260.
26. Whelan, K, Judd, PA & Taylor, MA (2004) Assessment of fecal output in patients receiving enteral tube feeding: validation of a novel chart. Eur J Clin Nutr 58, 10301037.
27. Whelan, K, Judd, PA, Preedy, VR et al. (2008) Covert assessment of concurrent and construct validity of a chart to characterize fecal output and diarrhea in patients receiving enteral nutrition. J Parenter Enteral Nutr 32, 160168.
28. Whelan, K, Hill, L, Preedy, VR et al. (2006) Formula delivery in patients receiving enteral tube feeding on general hospital wards: the impact of nasogastric extubation and diarrhea. Nutrition 22, 10251031.
29. Whelan, K, Judd, PA, Preedy, VR et al. (2004) Enteral feeding: the effect on faecal output, the faecal microflora and SCFA concentrations. Proc Nutr Soc 63, 105113.
30. Guenter, PA, Settle, RG, Perlmutter, S et al. (1991) Tube feeding related diarrhoea in acutely ill patients. J Parenter Enteral Nutr 15, 277280.
31. Sullivan, A, Edlund, C & Nord, CE (2001) Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1, 101114.
32. Bliss, DZ, Johnson, S, Savik, K et al. (1998) Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhoea in hospitalised patients receiving tube feeding. Ann Intern Med 129, 10121019.
33. Bowling, TE, Raimundo, AH, Grimble, GK et al. (1993) Reversal by short-chain fatty acids of colonic fluid secretion induced by enteral feeding. Lancet 342, 12661268.
34. Whelan, K, Judd, PA, Tuohy, KM et al. (2009) Fecal microbiota in patients receiving enteral feeding are highly variable and may be altered in those who develop diarrhea. Am J Clin Nutr 89, 240247.
35. Whelan, K, Judd, PA, Preedy, VR et al. (2005) Fructo-oligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans. J Nutr 135, 18961902.
36. Benus, R, van der Werf, T, Welling, GW et al. (2010) Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy humans. Br J Nutr 104, 693700.
37. Whelan, K, Gibson, GR, Judd, PA et al. (2001) The role of probiotics and prebiotics in the management of diarrhoea associated with enteral tube feeding. J Hum Nutr Diet 14, 423433.
38. Whelan, K (2007) Enteral tube feeding diarrhoea: manipulating the colonic microbiota with probiotics and prebiotics. Proc Nutr Soc 66, 299306.
39. Whelan, K, Efthymiou, L, Judd, PA et al. (2006) Appetite during consumption of enteral formula as a sole source of nutrition: the effect of supplementing pea-fibre and fructo-oligosaccharides. Br J Nutr 96, 350356.
40. Schneider, SM, Girard-Pipau, F, Anty, R et al. (2006) Effects of total enteral nutrition supplemented with a multi-fibre mix on faecal short-chain fatty acids and microbiota. Clin Nutr 25, 8290.
41. Majid, HA, Emery, PW & Whelan, K (2011) Faecal microbiota and short-chain fatty acids in patients receiving enteral nutrition with standard or FOS and fibre-enriched formulas. J Hum Nutr Diet 24, 260268.
42. Sobotka, L, Brátova, M, Slemrová, M et al. (1997) Inulin as the soluble fiber in liquid enteral nutrition. Nutrition 13, 2125.
43. Wierdsma, NJ, van Bodegraven, AA, Uitdehaag, BM et al. (2009) Fructo-oligosaccharides and fibre in enteral nutrition has a beneficial influence on microbiota and gastrointestinal quality of life. Scand J Gastroenterol 44, 804812.
44. Majid, HA, Cole, J, Sherry, T et al. (2012) A multi-centre, randomised, double-blind, controlled trial determining the effect of additional fructo-oligosaccharides on fecal microbiota and short-chain fatty acids among critical care patients receiving enteral nutrition. Gastroenterology 142, Suppl. 1, S909.
45. Hickson, M, D'Souza, AL, Muthu, N et al. (2007) Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335, 80.
46. Parkes, GC, Sanderson, JD & Whelan, K (2009) The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 9, 237244.
47. Whelan, K & Schneider, SM (2011) Mechanisms, prevention, and management of diarrhea in enteral nutrition. Curr Opin Gastroenterol 27, 152159.
48. Bleichner, G, Blehaut, H, Mentec, H et al. (1997) Saccharomyces boulardii prevents diarrhoea in critically ill tube fed patients. Intensive Care Med 23, 517523.
49. Frohmader, TJ, Chaboyer, WP, Robertson, IK et al. (2010) Decrease in frequency of liquid stool in enterally fed critically ill patients given the multispecies probiotic VSL#3: a pilot trial. Am J Crit Care 19, e1e11.
50. Whelan, K & Myers, CE (2010) Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr 91, 687703.
51. Loftus, EV Jr. (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology 126, 15041517.
52. Gerasimidis, K, McGrogan, P & Edwards, CA (2011) The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet 24, 313326.
53. Prince, A, Whelan, K, Moosa, A et al. (2011) Nutritional problems in inflammatory bowel disease: the patient perspective. J Crohn's Colitis 5, 443450.
54. Irvine, EJ (1997) Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol 92, Suppl. 12, S18S24.
55. Dignass, A, Van Assche, G, Lindsay, JO et al. (2010) The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 4, 2862.
56. Zachos, M, Tondeur, M & Griffiths, AM (2007) Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev CD000542.
57. Lomer, MC, Gourgey, R & Whelan, K (2013) Current practice in relation to nutritional assessment and dietary management of enteral nutrition in adults with Crohn's disease. J Hum Nutr Diet (In the Press).
58. Sellon, RK, Tonkonogy, S, Schultz, M et al. (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66, 52245231.
59. Fasoli, R, Kettlewell, MG, Mortensen, N et al. (1990) Response to faecal challenge in defunctioned colonic Crohn's disease: prediction of long-term course. Br J Surg 77, 616617.
60. Hugot, JP, Chamaillard, M, Zouali, H et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599603.
61. Lees, CW, Barrett, JC, Parkes, M et al. (2011) New IBD genetics: common pathways with other diseases. Gut 60, 17391753.
62. Willing, BP, Dicksved, J, Halfvarson, J et al. (2010) A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139, 18441854.
63. Tozer, PJ, Whelan, K, Phillips, RK et al. (2009) Etiology of perianal Crohn's disease: role of genetic, microbiological, and immunological factors. Inflamm Bowel Dis 15, 15911598.
64. Benjamin, JL, Hedin, CRH, Koutsoumpas, A et al. (2012) Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 18, 10921100.
65. Seksik, P, Rigottier-Gois, L, Gramet, G et al. (2003) Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52, 237242.
66. Sokol, H, Seksik, P, Furet, JP et al. (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15, 11831189.
67. Hart, AL, Lammers, K & Brigidi, P (2004) Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53, 16021609.
68. Ng, SC, Benjamin, JL, McCarthy, NE et al. (2012) The relationship between human intestinal dendritic cells, gut microbiota and disease activity in Crohn's disease. Inflamm Bowel Dis 17, 20272037.
69. Sokol, H, Pigneur, B, Watterlot, L et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. Proc Natl Acad Sci USA 105, 1673116736.
70. Ramirez-Farias, C, Slezak, K, Fuller, Z et al. (2009) Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii . Br J Nutr 101, 541550.
71. Cavaglieri, CR, Nishiyama, A, Fernandes, LC et al. (2003) Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci 73, 16831690.
72. Hedin, C, Whelan, K & Lindsay, JO (2007) Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 66, 307315.
73. Koleva, PT, Valcheva, RS, Sun, X et al. (2012) Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr 108, 16331643.
74. Lindsay, JO, Whelan, K, Stagg, AJ et al. (2006) Clinical, microbiological and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55, 348355.
75. Benjamin, JL, Hedin, CRH, Koutsoumpas, A et al. (2011) A randomised, double blind placebo controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 60, 923929.
76. Joossens, M, De Preter, V, Ballet, V et al. (2012) Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial. Gut 61, 958.
77. Hedin, CR, Stagg, AJ, Whelan, K et al. (2012) Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut 61, 311318.
78. Hedin, CRH, Mullard, M, Sharratt, E et al. (2010) Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 16, 20992108.
79. Jonkers, D, Penders, J, Masclee, A et al. (2012) Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 72, 803823.
80. Anderson, JL, Edney, RJ & Whelan, K (2012) Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36, 503516.
81. Agarwal, N & Spiegel, BM (2011) The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am 40, 1119.
82. Parkes, GC, Brostoff, J, Whelan, K et al. (2008) Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103, 15571567.
83. Marshall, JK, Thabane, M, Garg, AX et al. (2006) Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 131, 445450.
84. Marshall, JK, Thabane, M, Garg, AX et al. (2010) Eight year prognosis of post-infectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 59, 605611.
85. Kassinen, A, Krogius-Kurikka, L, Mäkivuokko, H et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133, 2433.
86. Parkes, GC, Rayment, NB, Hudspith, BN et al. (2012) Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 24, 3139.
87. Shah, ED, Basseri, RJ, Chong, K et al. (2010) Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci 55, 24412449.
88. Whelan, K (2011) Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 14, 581587.
89. Hunter, JO, Tuffnell, Q & Lee, AJ (1998) Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr 129, Suppl. 7, S1451S1453.
90. Olesen, M & Gudmand-Hoyer, E (2000) Efficacy, safety, and tolerability of fructo-oligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr 72, 15701575.
91. Paineau, D, Payen, F, Panserieu, S et al. (2008) The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr 99, 311318.
92. Silk, DB, Davis, A, Vulevic, J et al. (2009) Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29, 508518.
93. Ong, DK, Mitchell, SB, Barrett, JS et al. (2010) Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 25, 13661373.
94. Barrett, JS, Gearry, RB, Muir, JG et al. (2010) Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 31, 874882.
95. Staudacher, H, Whelan, K, Irving, P et al. (2011) Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 24, 487495.
96. Staudacher, HM, Lomer, MCE, Anderson, JL et al. (2012) Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 142, 15101518.
97. Simren, M, Barbara, G, Flint, HJ et al. (2013) Intestinal microbiota in functional bowel disorders: a Rome Foundation report. Gut 62, 159176.
98. McKenzie, YA, Alder, A, Anderson, W et al. (2012) British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 25, 260274.



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed